{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:20:57Z","timestamp":1765887657780},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,18]],"date-time":"2014-10-18T00:00:00Z","timestamp":1413590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10620-014-3392-z","type":"journal-article","created":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T05:52:53Z","timestamp":1413525173000},"page":"951-956","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series"],"prefix":"10.1007","volume":"60","author":[{"given":"Yun-Seong","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoung Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyoun Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,18]]},"reference":[{"key":"3392_CR1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","volume":"23","author":"P Rutgeerts","year":"2006","unstructured":"Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease\u2014seven years on. Aliment Pharmacol Ther. 2006;23:451\u2013463.","journal-title":"Aliment Pharmacol Ther"},{"key":"3392_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/CEOR.S15988","volume":"3","author":"J Norum","year":"2011","unstructured":"Norum J, Koldingsnes W, Aanes T, et al. The economic burden of TNF\u03b1 inhibitors and other biologic treatments in Norway. ClinicoEconomics Outcomes Res (CEOR). 2011;3:73.","journal-title":"ClinicoEconomics Outcomes Res (CEOR)"},{"key":"3392_CR3","unstructured":"World Health Organization. WHO expert committee on biological standardization. World Health Organ Tech Rep Ser. 2013;978:1\u2013384, back cover."},{"key":"3392_CR4","first-page":"2132","volume":"4","author":"SJ Kanase","year":"2013","unstructured":"Kanase SJ, Gavhane YN, Khandekar A, et al. Biosimilar: an overview. Int J Pharm Sci Res. 2013;4:2132\u20132144.","journal-title":"Int J Pharm Sci Res"},{"key":"3392_CR5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","volume":"1","author":"H Schellekens","year":"2002","unstructured":"Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1:457\u2013462.","journal-title":"Nat Rev Drug Discov"},{"key":"3392_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrclinonc.2009.113","volume":"6","author":"NN Malik","year":"2009","unstructured":"Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol. 2009;6:550\u2013552.","journal-title":"Nat Rev Clin Oncol"},{"key":"3392_CR7","unstructured":"Generic Pharmaceutical Association. Savings achieved through the use of generic pharmaceuticals 2000\u20132009. http:\/\/www.gphaonline.org\/sites\/default\/files\/GPhA%20Savings%20Study%20Book%20Updated%20Web%20FINAL%20Jul23%2010_0.pdf . Accessed 12 May 2011."},{"key":"3392_CR8","doi-asserted-by":"crossref","unstructured":"Epstein MS, Ehrenpreis ED, Kulkarni PM. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014. doi: 10.1038\/ajg.2014.151 .","DOI":"10.1038\/ajg.2014.151"},{"key":"3392_CR9","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"M Weise","year":"2012","unstructured":"Weise M, Bielsky M-C, De Smet K, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111\u20135117.","journal-title":"Blood"},{"key":"3392_CR10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613\u20131620.","journal-title":"Ann Rheum Dis"},{"key":"3392_CR11","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605\u20131612.","journal-title":"Ann Rheum Dis"},{"key":"3392_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"A Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management. J Crohn\u2019s Colitis. 2010;4:28\u201362.","journal-title":"J Crohn\u2019s Colitis"},{"key":"3392_CR13","volume-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations","author":"Food and Drug Administration","year":"2003","unstructured":"Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations. Washington, DC: Food and Drug Administration; 2003."},{"key":"3392_CR14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel J, Singleton J, et al. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1976;70:439\u2013444.","journal-title":"Gastroenterology"},{"key":"3392_CR15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","volume":"132","author":"G D\u2019Haens","year":"2007","unstructured":"D\u2019Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763\u2013786.","journal-title":"Gastroenterology"},{"key":"3392_CR16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, et al. Efficacy and safety of retreatment with anti\u2013tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology. 1999;117:761\u2013769.","journal-title":"Gastroenterology"},{"key":"3392_CR17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"3392_CR18","first-page":"17","volume":"30","author":"S Travis","year":"2006","unstructured":"Travis S, Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol. 2006;30:17.","journal-title":"Pract Gastroenterol"},{"key":"3392_CR19","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.gastro.2007.05.006","volume":"133","author":"M Clark","year":"2007","unstructured":"Clark M, Colombel J-F, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21\u201323, 2006. Gastroenterology. 2007;133:312\u2013339.","journal-title":"Gastroenterology"},{"key":"3392_CR20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for Crohn\u2019s disease. N Engl J Med. 1997;337:1029\u20131036.","journal-title":"N Engl J Med"},{"key":"3392_CR21","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"3392_CR22","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1046\/j.1440-1746.17.s1.1.x","volume":"17","author":"P Rutgeerts","year":"2002","unstructured":"Rutgeerts P. A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:S176\u2013S185.","journal-title":"J Gastroenterol Hepatol"},{"key":"3392_CR23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","volume":"53","author":"T Ljung","year":"2004","unstructured":"Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849\u2013853.","journal-title":"Gut"},{"key":"3392_CR24","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1053\/j.gastro.2005.01.010","volume":"128","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: act 1 trial. Gastroenterology. 2005;128:A105.","journal-title":"Gastroenterology"},{"key":"3392_CR25","doi-asserted-by":"crossref","first-page":"V6","DOI":"10.1055\/s-2005-869606","volume":"43","author":"W Sandborn","year":"2005","unstructured":"Sandborn W, Reinisch W, Rachmilewitz D, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the act 2 trial. Zeitschrift f\u00fcr Gastroenterologie. 2005;43:V6.","journal-title":"Zeitschrift f\u00fcr Gastroenterologie"},{"key":"3392_CR26","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","volume":"95","author":"RJ Farrell","year":"2000","unstructured":"Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn\u2019s disease. Am J Gastroenterol. 2000;95:3490\u20133497.","journal-title":"Am J Gastroenterol"},{"key":"3392_CR27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"J-F Colombel","year":"2004","unstructured":"Colombel J-F, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19\u201331.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3392-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3392-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3392-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T04:52:35Z","timestamp":1565931155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3392-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,18]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3392"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3392-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,18]]}}}